Rifaximin: beyond the traditional antibiotic activity
Open Access
- 6 August 2014
- journal article
- review article
- Published by Springer Nature in The Journal of Antibiotics
- Vol. 67 (9) , 667-670
Abstract
Rifaximin is a non-systemic oral antibiotic derived from rifampin and characterized by a broad spectrum of antibacterial activity against Gram-positive and -negative, aerobic and anaerobic bacteria. Rifaximin was first approved in Italy in 1987 and afterwards in many other worldwide countries for the treatment of several gastrointestinal diseases. This review updates the pharmacology and pharmacodynamics of rifaximin highlighting the different actions, beyond its antibacterial activity, such as alteration of virulence, prevention of gut mucosal adherence and bacterial translocation. Moreover, rifaximin exerts some anti-inflammatory effects with only a minimal effect on the overall composition of the gut microbiota. All these properties make rifaximin a good candidate to treat various gastrointestinal diseases.Keywords
This publication has 34 references indexed in Scilit:
- Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic EncephalopathyPLOS ONE, 2013
- Rifaximin Resistance in Escherichia coli Associated with Inflammatory Bowel Disease Correlates with Prior Rifaximin Use, Mutations in rpoB , and Activity of Phe-Arg-β-Naphthylamide-Inhibitable Efflux PumpsAntimicrobial Agents and Chemotherapy, 2013
- Effects of Antibiotics on Shiga Toxin 2 Production and Bacteriophage Induction by Epidemic Escherichia coli O104:H4 StrainAntimicrobial Agents and Chemotherapy, 2012
- Pregnane X receptor as a target for treatment of inflammatory bowel disordersTrends in Pharmacological Sciences, 2012
- Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in miceJournal of Hepatology, 2012
- Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn's DiseaseGastroenterology, 2012
- Therapeutic Role of Rifaximin in Inflammatory Bowel Disease: Clinical Implication of Human Pregnane X Receptor ActivationThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Bile Acids Improve the Antimicrobial Effect of RifaximinAntimicrobial Agents and Chemotherapy, 2010
- In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, TexasJournal of Clinical Pathology, 2010
- Pretreatment of Epithelial Cells with Rifaximin Alters Bacterial Attachment and Internalization ProfilesAntimicrobial Agents and Chemotherapy, 2010